BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 247 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q4 2020. The put-call ratio across all filers is 0.72 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,647,000 | +4.7% | 10,900 | +0.9% | 0.01% | +14.3% |
| Q2 2022 | $1,573,000 | +68.1% | 10,800 | +36.7% | 0.01% | +133.3% |
| Q1 2022 | $936,000 | -5.6% | 7,900 | +9.7% | 0.00% | 0.0% |
| Q4 2021 | $992,000 | -31.3% | 7,200 | -30.8% | 0.00% | -40.0% |
| Q3 2021 | $1,444,000 | +180.9% | 10,400 | +96.2% | 0.01% | +150.0% |
| Q2 2021 | $514,000 | +242.7% | 5,300 | +140.9% | 0.00% | +100.0% |
| Q1 2021 | $150,000 | -64.2% | 2,200 | -55.1% | 0.00% | -50.0% |
| Q4 2020 | $419,000 | +46.5% | 4,900 | +11.4% | 0.00% | +100.0% |
| Q3 2020 | $286,000 | -32.5% | 4,400 | -24.1% | 0.00% | -50.0% |
| Q2 2020 | $424,000 | -47.9% | 5,800 | -68.8% | 0.00% | -50.0% |
| Q2 2019 | $814,000 | +65.8% | 18,600 | +2.2% | 0.00% | +100.0% |
| Q4 2017 | $491,000 | -27.8% | 18,200 | 0.0% | 0.00% | -33.3% |
| Q3 2017 | $680,000 | +844.4% | 18,200 | +527.6% | 0.00% | – |
| Q2 2017 | $72,000 | – | 2,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 1,111,111 | $107,867,000 | 52.60% |
| Knoll Capital Management, LLC | 856,844 | $83,182,000 | 43.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,082,555 | $202,174,000 | 27.86% |
| ARS Investment Partners, LLC | 558,286 | $54,198,000 | 5.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $17,113,000 | 4.52% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 401,006 | $38,930,000 | 4.51% |
| Eventide Asset Management | 1,990,797 | $193,267,000 | 2.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 56,626 | $5,497,000 | 2.45% |
| Avidity Partners Management LP | 882,500 | $85,673,000 | 2.32% |
| Nicholas Investment Partners, LP | 363,708 | $35,309,000 | 2.22% |